Sponsor hub
Takeda clinical trial failures
Review 92 stopped clinical trials from Takeda, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 16 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 45
- OTHER/UNKNOWN
- 31
- SAFETY
- 9
- EFFICACY/FUTILITY
- 7
Notable sponsors
- Takeda
- 92
Related phases
- Phase I
- 35
- Phase II
- 24
- Phase III
- 23
- Phase IV
- 10
Crawlable stopped-trial records
Open ExploreShowing up to 92 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase III Dravet Syndrome (DS) trial by Takeda. Stop reason: OTHER/UNKNOWN.
Due to negative results from phase 3 SKYLINE and SKYWAY studies and unrelated to patient safety it has been determined that supplementary data from TAK-935-3003 study is no longer necessary. Therefore, Takeda has made a decision to close this study
Phase II Erosive Esophagitis trial by Takeda. Stop reason: OTHER/UNKNOWN.
Study related
Phase IV Multiple Myeloma trial by Takeda. Stop reason: OTHER/UNKNOWN.
All participants on the study have concluded treatment, core study activities are complete, and the scientific goals of the study have been met.
Phase I Leukemia trial by Takeda. Stop reason: OPERATIONAL.
Sponsor decision (No safety concern)
Phase II Epilepsy trial by Takeda. Stop reason: OPERATIONAL.
Due to negative results from phase 3 SKYLINE and SKYWAY studies and unrelated to patient safety it has been determined that supplementary data from TAK-935-18-001 study is no longer necessary. Therefore, Takeda has made a decision to close this study
Phase IV Crohn's Disease trial by Takeda. Stop reason: OPERATIONAL.
Sponsor decision
Phase I Pancreatic Cancer trial by Takeda. Stop reason: EFFICACY/FUTILITY.
Clinical Futility of TAK 500 met. No further development with this compound
Phase IV Mucopolysaccharidosis (MPS) trial by Takeda. Stop reason: OPERATIONAL.
Study was closed due to enrollment challenges
Phase I Squamous Cell Cancer of Head and Neck (SCCHN) trial by Takeda. Stop reason: OPERATIONAL.
Sponsor decision based on limited anti-cancer activity of TAK-186.
Phase III Crohn's Disease trial by Takeda. Stop reason: OPERATIONAL.
Sponsor decision
Phase I Solid Tumors trial by Takeda. Stop reason: OPERATIONAL.
Business reasons
Phase I Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) trial by Takeda. Stop reason: OPERATIONAL.
Phase 1 enrollment was terminated due to dose-limiting toxicities, thus the study was terminated by Sponsor.
Phase II Sleep Apnea trial by Takeda. Stop reason: OPERATIONAL.
Business decision unrelated to patient safety.
Phase I Unresectable Locally Advanced or Metastatic Cancer trial by Takeda. Stop reason: OTHER/UNKNOWN.
Terminated due to limited anti-cancer activity
Phase I Steatohepatitis trial by Takeda. Stop reason: OPERATIONAL.
Study was terminated early by the sponsor due to a strategic shift and reprioritization of clinical programs within Takeda.
Phase III Dravet Syndrome (DS) trial by Takeda. Stop reason: OPERATIONAL.
Business decision unrelated to patient safety.
Phase I Nausea and Vomitting trial by Takeda. Stop reason: OPERATIONAL.
Due to business reasons prior to first subject dosed.
Phase I Solid Tumors trial by Takeda. Stop reason: OPERATIONAL.
Business decision unrelated to patient safety
Phase I Solid Tumors trial by Takeda. Stop reason: OPERATIONAL.
Business decision unrelated to patient safety
Phase I Refractory Lupus Nephritis trial by Takeda. Stop reason: OPERATIONAL.
Business decision (no safety concerns)
Phase I Healthy Volunteers trial by Takeda. Stop reason: OPERATIONAL.
The study was terminated based on the Sponsor's decision attributed to the benefit-risk profile derived from the Part 1 data of this study.
Phase I Neoplasms trial by Takeda. Stop reason: OPERATIONAL.
Enrolment Challenges
Phase II Narcolepsy Type 1 (NT1) trial by Takeda. Stop reason: OTHER/UNKNOWN.
A safety signal has emerged in Phase 2 studies of TAK-994. As an immediate precautionary measure, Takeda has suspended dosing of patients and has decided to stop Phase 2 studies early.
Phase I Relapsed and/or Refractory Multiple Myeloma (RRMM) trial by Takeda. Stop reason: OPERATIONAL.
Business Reasons
Phase I Lymphoma, Non-Hodgkin trial by Takeda. Stop reason: OPERATIONAL.
Enrolment Challenges
Phase III Constipation trial by Takeda. Stop reason: EFFICACY/FUTILITY.
Data Monitoring Committee (DMC) decision; terminated due to futility, with no safety concerns; FDA agreement to terminate the study.
Phase II Healthy Volunteers trial by Takeda. Stop reason: OTHER/UNKNOWN.
Business reason, change in Zika virus epidemiology
Phase II Narcolepsy Type 1 (NT 1) trial by Takeda. Stop reason: OTHER/UNKNOWN.
A safety signal has emerged in Phase 2 studies of TAK-994. As an immediate precautionary measure, Takeda has suspended dosing of patients and has decided to stop Phase 2 studies early.
Phase IV Colitis, Ulcerative trial by Takeda. Stop reason: OTHER/UNKNOWN.
Early Completed - Alternative Source of Drug Available
Phase II Crohn Disease trial by Takeda. Stop reason: OPERATIONAL.
Sponsor decision to discontinue study due to inability to recruit the expected number of subjects within the requisite time period.
Phase IV Chronic Obstructive Pulmonary Disease (COPD) trial by Takeda. Stop reason: OPERATIONAL.
Business decision
Phase I Healthy Volunteers trial by Takeda. Stop reason: OTHER/UNKNOWN.
Study not needed
Phase IV Multiple Myeloma trial by Takeda. Stop reason: OPERATIONAL.
Business decision (no enrollment)
Phase I Healthy Volunteers trial by Takeda. Stop reason: OPERATIONAL.
Business decision
Phase I Healthy Volunteers trial by Takeda. Stop reason: OTHER/UNKNOWN.
The study stopped early, before enrolling its first participant.
Phase II Myelodysplastic Syndromes (MDS) trial by Takeda. Stop reason: OPERATIONAL.
Sponsor Decision to Terminate Trial
Phase I Healthy Volunteers trial by Takeda. Stop reason: OPERATIONAL.
Study was prematurely terminated because of administrative reasons.
Phase II Non-Small Cell Lung Cancer (NSCLC) trial by Takeda. Stop reason: OPERATIONAL.
Business Decision (no safety or efficacy concerns)
Phase IV Colitis, Ulcerative trial by Takeda. Stop reason: OPERATIONAL.
No enrollment
Phase I Coronavirus Disease trial by Takeda. Stop reason: OPERATIONAL.
Business Decision (no enrollment)
Phase I Pediatric Gastroesophageal Reflux Disease trial by Takeda. Stop reason: OPERATIONAL.
Withdrawn: Business decision (no enrollment)
Phase I Relapsed and/or Refractory Multiple Myeloma trial by Takeda. Stop reason: OPERATIONAL.
Business Decision; No Safety Or Efficacy Concerns
Phase I Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma trial by Takeda. Stop reason: OTHER/UNKNOWN.
Business reason unrelated to product safety
Phase I Poliomyelitis trial by Takeda. Stop reason: OTHER/UNKNOWN.
Planned immunogenicity outcomes not reached
Phase II Multiple Myeloma trial by Takeda. Stop reason: OPERATIONAL.
Business decision (no safety or efficacy concerns)
Phase III Mild Cognitive Impairment Due to Alzheimer's Disease trial by Takeda. Stop reason: EFFICACY/FUTILITY.
Lack of efficacy of the drug; no safety concern
Phase I Healthy Volunteers trial by Takeda. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Mild Cognitive Impairment Due to Alzheimer's Disease trial by Takeda. Stop reason: EFFICACY/FUTILITY.
Lack of efficacy of the drug; no safety concern
Phase I Healthy Volunteers trial by Takeda. Stop reason: OTHER/UNKNOWN.
Terminated prematurely due to indication change.
Phase I Alzheimer Disease trial by Takeda. Stop reason: OTHER/UNKNOWN.
Terminated prematurely as data from cohort no longer needed due to indication change.
Phase I Lupus Nephritis trial by Takeda. Stop reason: OPERATIONAL.
Insufficient enrollment, no safety or efficacy concerns
Phase III Erosive Esophagitis trial by Takeda. Stop reason: OTHER/UNKNOWN.
Compound is not expected to change the current treatment practice or fill significant clinical need for patients in China over currently available EE agents.
Phase II Rheumatoid Arthritis trial by Takeda. Stop reason: OPERATIONAL.
Strategic decision - to understand data from psoriasis study - NCT02129777 and wait for results of formal proof of concept study - NCT02379091.
Phase III Urinary Tract Infection trial by Takeda. Stop reason: OPERATIONAL.
Study was prematurely terminated due to administrative and strategic reasons
Phase IV Diabetes Mellitus, Type 2 trial by Takeda. Stop reason: OPERATIONAL.
Business decision, no safety or efficacy concerns
Phase II Diabetic Nephropathy trial by Takeda. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Hypertension trial by Takeda. Stop reason: OPERATIONAL.
Business reasons unrelated to product safety
Phase II Low Testosterone trial by Takeda. Stop reason: OPERATIONAL.
Sponsor decision to terminate the study because the study did not meet the primary endpoint.
Phase II Barrett's Esophagus trial by Takeda. Stop reason: OPERATIONAL.
Business Decisions; No Safety Concerns
Phase I Schizophrenia trial by Takeda. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Hypogonadotropic Hypogonadism trial by Takeda. Stop reason: OPERATIONAL.
Sponsor decision to terminate the study because the study did not achieve the primary efficacy objective.
Phase III Primary Sclerosing Cholangitis trial by Takeda. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Healthy Japanese and Caucasian Male Adults trial by Takeda. Stop reason: OPERATIONAL.
Business decision; No Safety or Efficacy Concerns
Phase II Type 2 Diabetes Mellitus trial by Takeda. Stop reason: SAFETY.
Due to potential concerns about liver safety (See Detailed Description)
Phase II Papillomavirus Infections trial by Takeda. Stop reason: EFFICACY/FUTILITY.
Lack of efficacy
Phase II Ulcerative Colitis trial by Takeda. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Influenza Prevention trial by Takeda. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Papillomavirus Infections trial by Takeda. Stop reason: EFFICACY/FUTILITY.
Lack of efficacy
Phase I Safety trial by Takeda. Stop reason: OTHER/UNKNOWN.
Long-term animal toxicology findings (see detailed description).
Phase I Attention-Deficit/Hyperactivity Disorder trial by Takeda. Stop reason: OTHER/UNKNOWN.
To allow evaluation of emerging non-clinical data (see detailed description below)
Phase II Diabetes Mellitus trial by Takeda. Stop reason: SAFETY.
Animal Toxicity Findings
Phase III Hypercholesterolemia trial by Takeda. Stop reason: OTHER/UNKNOWN.
Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents
Phase III Glycemic Control trial by Takeda. Stop reason: SAFETY.
Due to concerns about potential liver safety (See Detailed Description)
Phase III Diabetes Mellitus, Type 2 trial by Takeda. Stop reason: SAFETY.
Due to potential concerns about liver safety (See Detailed Description)
Phase III Diabetes trial by Takeda. Stop reason: SAFETY.
Due to potential concerns about liver safety (See Detailed Description)
Phase III Diabetes Mellitus, Type 2 trial by Takeda. Stop reason: SAFETY.
Due to potential concerns about liver safety (See Detailed Description)
Phase IV Essential Hypertension With Stable Angina and Dyslipidemia trial by Takeda. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Bipolar Disorder trial by Takeda. Stop reason: OPERATIONAL.
Business Decision; No Safety Concerns.
Phase III Acute Depressive Episode trial by Takeda. Stop reason: OPERATIONAL.
Business Decision; No Safety Concerns
Phase II Rheumatoid Arthritis trial by Takeda. Stop reason: OTHER/UNKNOWN.
Trial re-design; no safety issues identified
Phase IV Weight Regain Post Bariatric Surgery trial by Takeda. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Bipolar Disorder trial by Takeda. Stop reason: EFFICACY/FUTILITY.
Business Decision; Terminated due to futility, with no safety concerns (see below)
Phase II Erectile Dysfunction trial by Takeda. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Carcinoma, Non-Small-Cell Lung trial by Takeda. Stop reason: OPERATIONAL.
Sponsor decision to terminate the study because the study did not meet the primary endpoint.
Phase II Atherosclerotic Cardiovascular Disease trial by Takeda. Stop reason: OTHER/UNKNOWN.
Study has withdrawn.
Phase I Healthy Japanese Adult Male trial by Takeda. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Type 2 Diabetes Mellitus trial by Takeda. Stop reason: SAFETY.
Due to potential concerns about liver safety (See Detailed Description)
Phase III Type 2 Diabetes trial by Takeda. Stop reason: SAFETY.
Due to potential concerns about liver safety (See Detailed Description)
Phase III Diabetes Mellitus, Type 2 trial by Takeda. Stop reason: SAFETY.
Due to potential concerns about liver safety (See Detailed Description)
Phase I Healthy Volunteers trial by Takeda. Stop reason: OTHER/UNKNOWN.
Site non-compliance to GCP (No safety concerns. See detailed description)
Phase III Hypertension trial by Takeda. Stop reason: OPERATIONAL.
Business Decision; No Safety Or Efficacy Concerns. (See below)
Phase I Schizophrenia trial by Takeda. Stop reason: OPERATIONAL.
Business Decision; No Safety or Efficacy Concerns